HIL Medical logo

Lior Buchman, CPA – Board Director

Mr. Buchman has over 20 years of experience in senior corporate financing, mergers & acquisitions, investor relations, operational and business development. Currently the CFO of Integra Holdings Ltd, he has served as CFO of numerous international medical-device and life sciences companies – including Stryker GI (formerly Sightline Technologies), and others.
Mr. Buchman has extensive experience in equity and debt financing with over $150 Million aggregate capital raised and M&A including post-closing integration into the acquiring organizations.
He is a CPA (Isr.), and holds a BA in Accounting and Economics from the University of Haifa.

Roee Nagler, B.Sc , Commander (Ret.) – Acting Chief Executive Officer 

Roee brings over 25 years of experience in leadership and management at the highest levels.

He spent most of his career in the Israeli Navy, first serving as the Commanding Officer of several advanced warships and submarines, then moving on to lead numerous navy-wide multidisciplinary technological and infrastructure projects. Among other things, Roee served as Head of the operational characterization team for the future submarines, Director of the submarine fleet projects branch, and others – and was endowed with the Israel Security Award.

Upon retiring at the rank of Commander Roee served as the Vice-President of Operations at Totem-Plus – a company developing and manufacturing infrastructure and systems for the maritime industry – and held leadership positions in several Defense development projects with I.A.I (Israel Aerospace Industries), Elbit and Rafael.

Roee is member of the Maritime Policy & Strategy center at the University of Haifa and graduate of the US Naval Command College in Newport, RI, as well as of the Israeli Naval Officers’ Academy in Haifa. He holds a BSc in Industrial Engineering Suma Cum Laude.

Morris Laster, MD – Board Director

Dr. Laster is a healthcare executive/entrepreneur with over 25 years of experience in the biopharmaceutical and medical-device industries.
Currently he is a Venture Partner responsible for Medtech investments at OurCrowd, and the Founder of Clil Medical and Xerem Medical.
Dr. Laster has founded 6 companies that have gone public in the US, UK and Israel. He was the Founder and Director of Kitov Pharmaceuticals (TASE: KTOV), Founding CEO of BioLineRX (dually-listed on NASDAQ and TASE: BLRX), and Chairman and CEO of Keryx Biopharmaceuticals (NASDAQ:KERX) – where he led the first simultaneous NASDAQ/AIM listing in 2000.
Dr. Laster began his entrepreneurial career as a VP of medical venture capital at Paramount Capital in NYC. While in that capacity he founded three companies that went public: XTL Therapeutics (NASDAQ:XTLB) – which developed hepatitis B and C antibodies in programs that were licensed to Cubist, Progenitor (NASDAQ:PGEN), and Neose Technologies (NASDAQ: NTEC).
He received his MD from Downstate Medical Center, Brooklyn, NY in 1990 and a BS in Biology from SUNY Albany.